Omeprazole Omeprazole

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Bayer AG","sponsor":"Carlin Consumer Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hildred Capital Management, LLC, Bourne Partners Strategic Capital and The Emerson Group Launch Carlin Consumer Health","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azurity Pharmaceuticals, Inc. Announces FDA Approval of Konvomep\u2122 (Omeprazole and Sodium Bicarbonate for Oral Suspension)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Brand Institute","sponsor":"Azurity Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brand Institute Partners on Brand Name Development for FDA Approved Treatment for Active Benign Gastric Ulcer and Reduction of Risk of Upper Gastrointestinal Bleeding in Critically Ill Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia\u00ae with IP Protection Running to 2034","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for ( -)-Omeprazole

    Menu

    ( -)-Omeprazole

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              RedHill Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034

              Details:

              Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection in adults.

              Lead Product(s): Amoxicillin Trihydrate,Rifabutin,Omeprazole

              Therapeutic Area: Infections and Infectious Diseases Product Name: Talicia

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Brand Institute

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Brand Institute Partners on Brand Name Development for FDA Approved Treatment for Active Benign Gastric Ulcer and Reduction of Risk of Upper Gastrointestinal Bleeding in Cr...

              Details:

              KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension) is a medication indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill adult patients.

              Lead Product(s): Omeprazole,Sodium Bicarbonate

              Therapeutic Area: Gastroenterology Product Name: Konvomep

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Azurity Pharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Azurity Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Azurity Pharmaceuticals, Inc. Announces FDA Approval of Konvomep™ (Omeprazole and Sodium Bicarbonate for Oral Suspension)

              Details:

              Konvomep™ (omeprazole and sodium bicarbonate for oral suspension) is approved for the treatment of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill patients.

              Lead Product(s): Omeprazole,Sodium Bicarbonate

              Therapeutic Area: Gastroenterology Product Name: Konvomep

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bayer AG

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hildred Capital Management, LLC, Bourne Partners Strategic Capital and The Emerson Group Launch Carlin Consumer Health

              Details:

              Carlin will be uniquely positioned to acquire and commercialize well-established brands as well as support its retail partners and their customers, in connection with this, Carlin announced the acquisition of Zegerid OTC® (“Zegerid”) from Bayer AG.

              Lead Product(s): Omeprazole,Sodium Bicarbonate

              Therapeutic Area: Gastroenterology Product Name: Zegerid

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Carlin Consumer Health

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition February 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY